Use of lacosamide as the last antiepileptic drug (AED) a patient is administered for status epilepticus (SE) is "strongly associated with termination of status." VANCOUVER, BC—Use of lacosamide as the ...

Vomiting 2.5 5.9 8.5 Vision blurred 2.5 2.2 8.5 Somnolence 4.7 5.2 8.1 Nasopharyngitis 5.8 6.3 7.6 Fatigue 5.8 7.0 7.2 Coordination abnormal 1.6 4.1 7.2 Tremor 4.1 3.7 6.2 Balance disorder 0.0 1.1 5.1 ...

Topline results of a phase 3 trial support a supplemental New Drug Application for lacosamide (Vimpat, UCB) as monotherapy for patients with partial-onset seizures, the company has announced.

Review the side-effects of Lacosamide as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Discover comprehensive details about Lacosamide, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

NEW ORLEANS – The anti-epileptic agent lacosamide (Vimpat) appears to give relief to patients with refractory trigeminal neuralgia, researchers reported here. Principal investigator Jeffrey Cohen, MD, ...

Alembic Pharmaceuticals Limited has received final approval for Lacosamide Tablets from the US Food and Drug Administration (USFDA). It is used for the treatment of partial-onset seizures in patients ...

A recent multi-center study has confirmed earlier study results that 400 mg/day of lacosamide provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seizures ...

BRUSSELS, Nov 29 (Reuters) - Belgian pharmaceutical group UCB said on Thursday that it had filed for approval with the U.S. Food and Drug Administration (FDA) its drug lacosamide for treating epilepsy ...